VVelarionINTELLIGENCE
Sign inStart free trial
Start free trial
Biopharma & Life Sciences

Minerva Neurosciences Executive Compensation (FY25)

NERV · Executive and director compensation, fiscal 2022 to 2025
Chief executive, fiscal 2025
◇
Remy Luthringer
Latest say-on-pay support
=
June 3, 2026
Velarion Member: every covered company in Biopharma & Life Sciences, with dashboards, peer screens and board-ready briefs. Three seats, one year.
Email me this page as a cited PDF — sent in 2 minutes
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.

The paid brief on Minerva Neurosciences

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $499 for the board report; $2,400 for both.
Get the executive briefGet the board briefNo account needed.
Data as of October 27, 2026Latest filing (8-K): June 4, 2026
10 filings cited on this page
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Minerva Neurosciences brief$1,500Get the executive brief
Velarion Intel, one year, every company
149 figures on this page: 142 cited to the filing that reported them, 7 calculated from figures it prints. See the citations

More on Minerva Neurosciences

Five data products on this company. Each one is requested through the developer setup page.
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Remy Luthringer: $1,209,984 → $9,354,184
Say-on-pay support: 99.3% → 89.5% (9.8 points lower)

Frequently asked questions

Answers drawn from the data on this page.
Who is Minerva Neurosciences' chief executive and what were they paid?
Total compensation for Remy Luthringer, Chief Executive Officer, came to $9,354,184 in fiscal 2025. Luthringer's total was up from the $1,209,984 reported for fiscal 2024.
What was Minerva Neurosciences' say-on-pay result?
Shareholders supported the say-on-pay proposal with 89.5% of votes cast for or against in favor at the meeting held June 3, 2026 for fiscal 2025.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Remy Luthringer
Chief Executive Officer
◇◇—◇——◇◇
Geoffrey Race
President
◇◇—◇——◇◇
Frederick Ahlholm
SVP, Chief Financial Officer and Secretary
◇◇—◇——◇◇
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Remy Luthringer
Chief Executive Officer
◇◇—◇——◇◇
Geoffrey Race
President
◇◇—◇——◇◇
Frederick Ahlholm
Chief Financial Officer
◇◇—◇——◇◇
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Remy Luthringer
Chief Executive Officer
◇◇—◇——◇◇
Geoffrey Race
President
◇◇—◇——◇◇
Frederick Ahlholm
Chief Financial Officer
◇◇—◇——◇◇
Fiscal 2025
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Remy Luthringer
Chief Executive Officer
◇◇—◇——◇◇
Geoffrey Race
Former President
Departed during or after this year
◇◇—◇——◇◇
Frederick Ahlholm
Chief Financial Officer
◇◇—◇——◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
Remy LuthringerOption◇—◇12/21/2035
PSU◇◇——
Option◇—◇12/4/2034
Option◇—◇10/3/2033
Option◇—◇12/12/2032
Option◇—◇2/15/2032
Geoffrey RaceOption◇—◇12/21/2035
Option◇—◇12/4/2034
PSU◇◇——
Option◇—◇10/3/2033
Option◇—◇12/12/2032
Option◇—◇2/15/2032
Frederick AhlholmOption◇—◇12/21/2035
Option◇—◇12/4/2034
Option◇—◇10/3/2033
PSU◇◇——
Option◇—◇12/12/2032
Option◇—◇2/15/2032
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director compensation

What each non-employee director was paid.
Fiscal 2025
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Dr. Inderjit Kaul
◇—◇——◇◇
Dr. David Kupfer
Lead independent director
◇—◇———◇
Hans Peter Hasler
◇—◇———◇
Jan van Heek
◇—◇———◇
Dr. Fouzia Laghrissi-Thode
◇—◇———◇
Dr. Remy Luthringer served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Total board retainer◇
Lead independent director premium◇
Audit committee chair◇
Audit committee member◇
Compensation committee chair◇
Compensation committee member◇
Nominating and governance chair◇
Nominating and governance member◇
Equity is delivered as Options.

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2025June 3, 2026=◇◇◇
2024December 22, 2025=◇◇◇
2023December 5, 2024=◇◇◇
2022September 27, 2023=◇◇◇
2021June 10, 2022=◇◇◇
2020June 11, 2021=◇◇◇
2019June 19, 2020=◇◇◇

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”
- Remy Luthringer (Chief Executive Officer), FY2025 total compensation $9,354,184 (base salary $675,027) [exec_comp, SEC accession 0001193125-26-171799, filed 2026-04-23]

See a complete sample report

Answered within 24 hours, every figure cited to its SEC filing. This is a one-off report: no refunds.

Tell me when Minerva Neurosciences files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact Minerva Neurosciences disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $499
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for Peer Group Review
Whether Minerva Neurosciences' disclosed peer group is defensible, who names Minerva Neurosciences back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
149 figures on this page: 142 cited to the filing that reported them, 7 calculated from figures it prints.
142 cited to the filing
7 calculated from the filing

Documents cited

  1. 0001193125-26-257379
    Item 5.07 Submission of Matters to a Vote of Security Holders
  2. 0001193125-26-171799
    DIRECTOR COMPENSATION · Outstanding Equity Awards at Fiscal Year-End · Summary Compensation Table
  3. 0001193125-25-328715
    Item 5.07 Submission of Matters to a Vote of Security Holders
  4. 0001193125-25-293674
    Summary Compensation Table
  5. 0001193125-24-271652
    Item 5.07 Submission of Matters to a Vote of Security Holders
  6. 0001193125-24-240733
    Summary Compensation Table
  7. 0001193125-23-245615
    Item 5.07 Submission of Matters to a Vote of Security Holders
  8. 0001193125-22-174803
    Item 5.07 Submission of Matters to a Vote of Security Holders
  9. 0001193125-21-192109
    Item 5.07 Submission of Matters to a Vote of Security Holders
  10. 0001193125-20-179182
    Item 5.07 Submission of Matters to a Vote of Security Holders
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Minerva Neurosciences executive compensation, FY2022–FY2025.” https://intel.velarion.ai/comp/NERV (accessed 2026).
Short form: data: Velarion

The paid brief for Minerva Neurosciences

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $499 for the board report; $2,400 for both.
Get the executive briefGet the board briefNo account needed.
10 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Minerva Neurosciences and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

Biopharma & Life Sciences rankings

Chief executive pay — Biopharma & Life SciencesCEO pay ratio — Biopharma & Life SciencesSay-on-pay support — Biopharma & Life Sciences

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies

Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.

Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  All companies · The Pay Desk · Methodology · Terms · Privacy